Stocks · News reference

Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial

Sep 28, 2026, 11:09 AMBenzinga Newsdesk

Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

TLSA

Source: benzinga
Observed: Sep 28, 2026, 11:09 AM
Checked: Sep 28, 2026, 11:09 AM
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

BenzingaOct 16, 2026, 11:05 AMBenzinga Newsdesk
Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027
Tiziana Life Sciences, Ltd. (NASDAQ:TLSA) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal
TLSA
BenzingaSep 30, 2026, 5:59 PMBenzinga Newsdesk
Tiziana Life Sciences shares are trading higher after the company announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy.
TLSA
BenzingaSep 30, 2026, 11:05 AMBenzinga Newsdesk
Tiziana Life Sciences Announces Submission Of FDA Orphan Drug Designation Request For Foralumab In Multiple System Atrophy
TLSA

Tiziana Life Sciences Says First Three Participants Receive First Dose Of Intranasal Foralumab In Phase 2a Healey ALS Mymatch BANYAN Clinical Trial

Connected Markets

Related Headlines

Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027

Tiziana Life Sciences shares are trading higher after the company announced that it has submitted a request to the FDA for Orphan Drug Designation for intranasal foralumab for the treatment of Multiple System Atrophy.

Tiziana Life Sciences Announces Submission Of FDA Orphan Drug Designation Request For Foralumab In Multiple System Atrophy